Here’s what you should know:
1. Takeda could sell Shire’s eye-disease treatment, Xiidra, and its hypoparathyroidism treatment, Natpara.
2. Analysts believe the two drugs could return up to $5 billion if sold.
3. The acquisition is expected to close in March 2019 if approved.
More articles on supply chain:
Mackinaw Surgery Center recognized by SPH Analytics — 3 insights
5 must-read articles for GI physicians this week: Sept. 6-12
How one ASC reduced infection rates while adding total joint procedures
